Bioventus BVS
$9.88 −$0.07 (-0.70%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.88 0.00%
Open$9.85
Prev close$9.95
Day range$9.81 – $10.17
Volume612.4K
Market cap$676.53M
P/E (TTM)12.2
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$142.44M+2.7% YoY
Operating profit$9.70M-13.8% YoY
Net profit$6.86M+71.2% YoY
Diluted EPS$0.08+60.0% YoY
Free cash flow$20.32M-31.4% YoY
Operating cash flow$20.66M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin68.7%
Operating margin10.1%
Net margin9.8%
Return on equity28.2%
Return on assets8.3%
Return on invested capital14.1%
Current ratio1.68
Liabilities / assets56.7%
Cash & investments$30.71M
Total debt$229.83M
Net cash (debt)-$199.12M
Free cash flow / sales14.5%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $142.44M | $153.21M | $132.09M | $568.09M | $157.90M |
| Total Operating Revenue | $142.44M | $153.21M | $132.09M | $568.09M | $157.90M |
| Cost of Revenue | $45.31M | $47.54M | $41.32M | $179.93M | $49.12M |
| Gross Profit | $97.13M | $105.67M | $90.77M | $388.16M | $108.78M |
| Operating Expense | $87.43M | $86.95M | $81.90M | $331.87M | $87.06M |
| Selling and Admin Expenses | $82.95M | $82.74M | $78.33M | $314.03M | $82.76M |
| Research & Development | $3.44M | $3.17M | $2.47M | $12.11M | $3.01M |
| Depreciation & Amortization & Depletion | $1.05M | $1.04M | $1.11M | $5.73M | $1.30M |
| -Depreciation & Amortization | $1.05M | $1.04M | $1.11M | $5.73M | $1.30M |
| Operating Profit | $9.70M | $18.71M | $8.87M | $56.29M | $21.72M |
| Net Non-Operating Interest Income (Expense) | -$3.76M | -$4.07M | -$4.33M | -$26.49M | -$5.31M |
| Non-Operating Interest Expense | $3.76M | $4.07M | $4.33M | $26.49M | $5.31M |
| Other Income (Expense) | $216,000.00 | $664,000.00 | -$27,000.00 | -$4.10M | -$2.27M |
| Special Income (Charges) | $0.00 | $415,000.00 | -$454,000.00 | -$2.64M | -$2.24M |
| -Less:Restructuring and Mergern & Acquisition | $0.00 | -$415,000.00 | $454,000.00 | $2.24M | $2.24M |
| -Gain on Sale of Property/Plant/Equipment | $0.00 | $0.00 | $0.00 | -$81,000.00 | $0.00 |
| Other Non-Operating Income (Expenses) | $216,000.00 | $249,000.00 | $427,000.00 | -$1.45M | -$37,000.00 |
| Pretax Profit | $6.16M | $15.31M | $4.52M | $25.71M | $14.14M |
| Tax | -$701,000.00 | -$20.90M | $571,000.00 | -$1.57M | -$3.18M |
| Net Profit | $6.86M | $36.21M | $3.95M | $27.27M | $17.32M |
| Profit from Continuing Operations | $6.86M | $36.21M | $3.95M | $27.27M | $17.32M |
| Minority Interests | $872,000.00 | $2.76M | $833,000.00 | $4.54M | $2.56M |
| Net Income to Parent Company | $5.99M | $33.44M | $3.11M | $22.73M | $14.76M |
| Net Income to Common Stockholders | $5.99M | $33.44M | $3.11M | $22.73M | $14.76M |
| Basic EPS | $0.09 | $0.49 | $0.05 | $0.34 | $0.22 |
| Diluted EPS | $0.08 | $0.47 | $0.04 | $0.33 | $0.21 |
| -Less:Impairment of Capital Assets | – | – | – | $0.00 | $0.00 |
| -Less:Other Special Charges | – | – | – | $326,000.00 | $0.00 |
| Net Income from Discontinuous Operations | – | – | – | $0.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $673.43M | $673.35M | $650.54M | $683.56M | $683.56M |
| Total Current Assets | $265.54M | $257.53M | $249.81M | $272.84M | $272.84M |
| Cash and Cash Equivalents & Short-Term Investments | $30.71M | $29.46M | $35.85M | $51.24M | $51.24M |
| -Cash and Cash Equivalents | $30.71M | $29.46M | $35.85M | $51.24M | $51.24M |
| Receivables | $138.23M | $138.41M | $120.53M | $128.30M | $128.30M |
| -Accounts Receivable | $138.23M | $138.41M | $120.53M | $128.30M | $128.30M |
| Inventory | $83.10M | $79.81M | $83.19M | $82.24M | $82.24M |
| Other Current Assets | $13.51M | $9.86M | $10.26M | $11.07M | $11.07M |
| Total Non-Current Assets | $407.89M | $415.82M | $400.73M | $410.72M | $410.72M |
| Net PPE | $23.54M | $24.75M | $25.98M | $27.02M | $27.02M |
| -Gross PPE | $23.54M | $24.75M | $25.98M | $81.29M | $81.29M |
| Goodwill and Other Intangible Assets | $351.39M | $358.51M | $367.12M | $375.88M | $375.88M |
| -Goodwill | $7.46M | $7.46M | $7.46M | $7.46M | $7.46M |
| -Other Intangible Assets | $343.93M | $351.05M | $359.66M | $368.42M | $368.42M |
| Non-Current Deferred Assets | $29.54M | $29.05M | $5.52M | $5.52M | $5.52M |
| Other Non-Current Assets | $3.42M | $3.51M | $2.10M | $2.29M | $2.29M |
| Total Liabilities | $381.56M | $395.93M | $416.27M | $455.11M | $455.11M |
| Total Current Liabilities | $157.70M | $152.45M | $148.10M | $160.38M | $160.38M |
| Payables | $31.51M | $26.36M | $28.86M | $16.06M | $16.06M |
| -Accounts Payable | $25.79M | $20.20M | $24.05M | $10.93M | $10.93M |
| -Total Tax Payable | $5.72M | $6.16M | $4.81M | $5.14M | $5.14M |
| Current Accrued Expenses | $79.02M | $78.05M | $74.20M | $101.70M | $101.70M |
| Short-Term Debt and Capital Lease Obligation | $18.75M | $18.75M | $18.75M | $15.00M | $15.00M |
| -Current Debt | $18.75M | $18.75M | $18.75M | $15.00M | $15.00M |
| Other Current Liabilities | $23.03M | $22.43M | $20.09M | $21.06M | $21.06M |
| Total Non-Current Liabilities | $223.85M | $243.48M | $268.18M | $294.73M | $294.73M |
| Long Term Debt and Capital Lease Obligation | $211.08M | $229.70M | $253.33M | $278.95M | $278.95M |
| -Long Term Debt | $211.08M | $229.70M | $253.33M | $278.95M | $278.95M |
| Non-Current Deferred Liabilities | $568,000.00 | $568,000.00 | $568,000.00 | $433,000.00 | $433,000.00 |
| Other Non-Current Liabilities | $12.21M | $13.21M | $14.29M | $15.35M | $15.35M |
| Total Equity | $291.87M | $277.41M | $234.27M | $228.45M | $228.45M |
| Stockholders' Equity | $240.50M | $228.31M | $188.90M | $184.11M | $184.11M |
| Capital Stock | $85,000.00 | $84,000.00 | $84,000.00 | $83,000.00 | $83,000.00 |
| -Common Stock | $85,000.00 | $84,000.00 | $84,000.00 | $83,000.00 | $83,000.00 |
| Additional Paid-In Capital | $532.95M | $527.93M | $522.91M | $520.85M | $520.85M |
| Retained Earnings | -$292.39M | -$298.38M | -$331.82M | -$334.93M | -$334.93M |
| Gains/Losses Not Affecting Retained Earnings | -$148,000.00 | -$1.33M | -$2.28M | -$1.90M | -$1.90M |
| Minority Interests | $51.38M | $49.11M | $45.36M | $44.34M | $44.34M |
| -Accumulated Depreciation | – | – | – | -$54.26M | -$54.26M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $20.66M | $19.87M | $8.93M | $74.67M | $37.97M |
| Net cash flow from continuing operations | $20.66M | $19.87M | $8.93M | $74.67M | $37.97M |
| Net Income from Continuing Operations | $6.86M | $36.21M | $3.95M | $27.27M | $17.32M |
| Gain/Loss from Continuing Operations | $43,000.00 | $54,000.00 | $54,000.00 | $47,000.00 | -$27,000.00 |
| Depreciation & Depletion & Amortization | $10.32M | $10.95M | $11.21M | $47.01M | $11.69M |
| Deferred Tax | -$487,000.00 | -$22.29M | $135,000.00 | -$909,000.00 | -$1.13M |
| Other Non-Cash Items | $63,000.00 | $170,000.00 | $275,000.00 | $1.16M | $155,000.00 |
| Change in Working Capital | -$935,000.00 | -$10.17M | -$10.18M | -$13.84M | $6.21M |
| -Change in Receivables | $152,000.00 | -$17.94M | $7.32M | -$916,000.00 | $1.89M |
| -Change in Inventory | -$3.53M | $2.96M | -$2.65M | $8.57M | $12.97M |
| -Change in Payables and Accrued Expense | $4.10M | $3.82M | -$15.37M | -$19.81M | -$4.44M |
| -Change In Other Working Capital | -$1.65M | $990,000.00 | $522,000.00 | -$1.68M | -$4.20M |
| Net cash flow from investing | -$1.83M | -$2.46M | -$574,000.00 | -$3.25M | -$580,000.00 |
| Net Cash Flow from Continuing Investing Activities | -$1.83M | -$2.46M | -$574,000.00 | -$3.25M | -$580,000.00 |
| Net PPE Purchase and Sale | -$334,000.00 | -$960,000.00 | -$574,000.00 | -$2.56M | -$580,000.00 |
| Net Business Purchase and Sale | $0.00 | – | – | -$686,000.00 | $0.00 |
| Net Investment Purchase and Sale | -$1.50M | – | – | $0.00 | $0.00 |
| Financing Cash Flow | -$17.58M | -$23.43M | -$23.14M | -$62.14M | -$28.45M |
| Net Cash Flow from Continuing Financing Activities | -$17.58M | -$23.43M | -$23.14M | -$62.14M | -$28.45M |
| Net Issuance Payments Of Debt | -$18.75M | -$23.75M | -$22.00M | -$42.91M | -$28.75M |
| Net Common Stock Issuance | $1.42M | $853,000.00 | $120,000.00 | $2.07M | $511,000.00 |
| Net Other Financing Charges | -$248,000.00 | -$535,000.00 | -$1.26M | -$21.30M | -$208,000.00 |
| Ending Cash Balance | $30.71M | $29.46M | $35.85M | $51.24M | $51.24M |
| Net Change in Cash | $1.24M | -$6.02M | -$14.78M | $9.29M | $8.94M |
| Beginning Cash Balance | $29.46M | $35.85M | $51.24M | $41.58M | $42.16M |
| Effect of Exchange Rate Changes | $11,000.00 | -$370,000.00 | -$608,000.00 | $371,000.00 | $133,000.00 |
| Free Cash Flow | $20.32M | $18.91M | $8.36M | $72.11M | $37.39M |
| Cash Flow from Discontinued Operating Activities | – | – | – | $0.00 | – |
No comments yet — be the first to weigh in on BVS.
Sign in to join the discussion.